New study Equazen® mumomega® 

SFI is happy to announce the first investigation that shows measurable anatomical changes (MRI scans) in the brain of infants in response to maternal supplementation with fatty acids using Equazen® mumomega®. The clinical trial was conducted at the Chelsea & Westminster Hospital London, UK and published in the scientific journal Prostaglandins Leukotrienes Essential Fatty Acids (PLEFA 138 (2018) 6-13). This is the first study to show maternal BSFA supplementation enhances newborn infant’s brain size and suggests differential sex sensitivity of fetal brains to pregnancy BSFA status.

Back to News